151 related articles for article (PubMed ID: 2425959)
1. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
van Groeningen CJ; Leyva A; O'Brien AM; Gall HE; Pinedo HM
Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and pharmacokinetic evaluation of fazarabine in children.
Heideman RL; Gillespie A; Ford H; Reaman GH; Balis FM; Tan C; Sato J; Ettinger LJ; Packer RJ; Poplack DG
Cancer Res; 1989 Sep; 49(18):5213-6. PubMed ID: 2475244
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
Curt GA; Kelley JA; Fine RL; Huguenin PN; Roth JS; Batist G; Jenkins J; Collins JM
Cancer Res; 1985 Jul; 45(7):3359-63. PubMed ID: 2408749
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
Bailey H; Tutsch KD; Arzoomanian RZ; Tombes MB; Alberti D; Bruggink J; Wilding G
Cancer Res; 1991 Feb; 51(4):1105-8. PubMed ID: 1705165
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
[TBL] [Abstract][Full Text] [Related]
8. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
9. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
[TBL] [Abstract][Full Text] [Related]
10. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
[TBL] [Abstract][Full Text] [Related]
13. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs.
Chabot GG; Rivard GE; Momparler RL
Cancer Res; 1983 Feb; 43(2):592-7. PubMed ID: 6184151
[TBL] [Abstract][Full Text] [Related]
14. Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line.
Grant S; Rauscher F; Margolin J; Cadman E
Cancer Res; 1982 Feb; 42(2):519-24. PubMed ID: 6173114
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
[TBL] [Abstract][Full Text] [Related]
17. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
Harman GS; Craig JB; Kuhn JG; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J; Tuttle RL; Lucas VS
Cancer Res; 1988 Aug; 48(16):4706-10. PubMed ID: 3396016
[TBL] [Abstract][Full Text] [Related]
18. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
Von Hoff DD; Kuhn JG; Havlin KA; Langevin AM; Brown TD; Weiss GR; Turner JN; Purvis J; Lucas VS; Bair KW
Cancer Res; 1990 Dec; 50(23):7496-500. PubMed ID: 2253197
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
O'Dwyer PJ; Hudes GR; Walczak J; Schilder R; LaCreta F; Rogers B; Cohen I; Kowal C; Whitfield L; Boyd RA
Cancer Res; 1992 Dec; 52(24):6746-53. PubMed ID: 1458462
[TBL] [Abstract][Full Text] [Related]
20. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]